FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece”
Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its 3CL protease biology-focused joint venture partner NLC Pharma, Ltd., today announced it has received an initial purchase order from its European distribution partner T-Cell Protect Hellas S.A. (“T-Cell Protect” or “T-Cell”) for fifty thousand (50,000) bottles of its Tollovid Daily™ dietary supplement formulated product to be marketed under the T-Cell Protect brand (www.tcellprotect.com). The initial 50,000-bottle purchase order is expected to give T-Cell Protect a sufficient amount of product to complete its initial planned roll-out of T-Cell Protect to a subset of its 11,000 store retail distribution network throughout Greece, while also providing T-Cell Protect with sufficient marketing information to evaluate the relative number of maximum strength Tollovid® bottles it will need to purchase to fulfill demand for the Greek market for the first half of 2022. T-Cell Protect is in the process of establishing manufacturing capabilities for Tollovid and Tollovid Daily that will service the European market as part of its related 30 European country license agreement with Todos.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista’s proprietary commercial-stage Videssa® breast cancer blood test.
For more information, please visit: Todos Medical Ltd.
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.